Member Since 2012
President of EMD Serono and Global Head of Innovative Medicine Franchises for Merck KGaA, Darmstadt, Germany
As President of EMD Serono and Global Head of the Innovative Medicine Franchises for Merck KGaA, Darmstadt, Germany, Andrew Paterson leads the North American biopharmaceutical business across the U.S. and Canada in addition to leading the global oncology and neurology & immunology specialty medicine franchises for the healthcare business of Merck KGaA, Darmstadt, Germany.
Prior to this, Paterson served as Senior Vice President, Head of U.S. and Global MS Franchise, where he oversaw all commercial operations for the franchise in the US and also led global marketing efforts for our MS therapies.
In his 23 years with the company, Andrew has held positions in Local, Regional and Global commercial functions across a variety of therapeutic areas including Neurology, Endocrinology, Fertility and Cardio-vascular.
He began his career with Merck KGaA, Darmstadt, Germany in 1998 as a Medical Sales Representative in the UK. He subsequently took on roles of increasing responsibility including first line Sales Manager, Marketing Manager and Business Unit Director. Global and Regional leadership roles followed. Most recently, his focus was on the preparation and execution of the global launch of a new therapy in MS and progressing pipeline therapies toward commercialization.
Paterson holds a BSc (Hons) in Biological Science from the University of Edinburgh and an Executive MBA from Ashridge Management College.
CEO Cancer Gold Standard™
Gold Standard Employer
Gold Standard Task force Participation
Task Force Member(s): Ellen Spencer, Manager, Office of the President
Life Sciences Consortium
LSC Task Force Participation
Task Force Member(s): Zhen Su, MD, MBA, Vice President of Medical Oncology
Project Data Sphere, LLC
an independent initiative of the Life Sciences Consortium
Data Provider to Project Data Sphere, LLC since 2015
We are the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. We focus exclusively on specialty care – integrating cutting-edge science with industry-leading patient support.
At EMD Serono, we recognized the potential of specialty pharmaceuticals and patient care long ago, and have been dedicated to delivering on their promise ever since.
We have a legacy of both trying to find solutions to hard to treat conditions, as well as developing patient assistance programs that help ensure that those who need our therapies are able to access them.
As one of the top five U.S. companies exclusively focused on specialty care, we see our innovation as a matter of balancing science with emotion – integrating our top minds in research and development with the insights from patients and health care practitioners confronting real- world concerns.